Human BioSciences, Inc. (“HBS”) is a multinational biotechnology company which has been designing, manufacturing, distributing, and marketing a range of advanced collagen-based wound care products for almost thirty years. SkinTemp® II, Medifil® II and Collatek® are examples of HBS’s ability to convert laboratory concepts into exceptional and affordable advanced wound care products. HBS’s proprietary, FDA cleared and Medicare reimbursable KollagenTM products are revolutionizing the wound care industry by reducing healing times, treatment costs, amputation rates, and wound recurrence.
HBS’s KollagenTM technology provides clinicians with products that enhance patient quality of life and lead industry standards. While the wound care industry has based its standards of care on moist wound healing, fragmentation of products and services has resulted in lengthy and inconsistent care. Now, HBS’s products advance moist wound healing standards by consistently delivering positive and cost-effective outcomes.
HBS’s KollagenTM works because it is analogous to human collagen. KollagenTM products are used to treat the entire spectrum of wounds and most types of burns. HBS delivers its KollagenTM technology to the wound site in the form of gels, dressings, and particle products. These products are easy to use and are applied directly to the wound, thereby delivering the body’s one common denominator in healing – properly configured collagen. This eliminates the need for products that are dependent on wound stage, wound surface or chemical growth factors.
1600s Wound care focuses on maintaining a dry wound environment. Dressings such as cotton linters, paper, feathers, and dust are used.
1800s Care givers use cotton gauze, knit fibers, nonwoven swabs, sleeve dressings, and adhesive paper.
1867 Lister introduces antiseptics.
1962 Winter's landmark study finds “moist wounds epithelialized more rapidly than dry wounds.”
1980s Hunt observes visible fibroblast activity in wounds within a couple of days of injury. There is increasing awareness that dressings do more than protect the wound; they can influence the normal physiologic response to wounding.
1990s Outcome-based protocols require that clinicians define and compare which treatments or therapies work best, at what cost, and in what length of time.
1991 KollagenTM wound management technology is developed. KollagenTM based dressings follow moist wound healing principles and enhance the body's natural healing process.
1994 Continued research confirms that intact collagen plays a key role in wound healing.
Present Increased use of biocompatible and bioabsorbable materials. Dressings are delivery systems for active agents, growth factors, and debridement agents. This has resulted in a fragmented market which includes a variety of different products that produce similar inconsistent results. KollagenTM technology remains unmatched in its ability to deliver consistent positive outcomes.